interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Isavuconazonium Sulfate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Isavuconazonium Sulfate, and who makes it?

Isavuconazonium Sulfate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Isavuconazonium Sulfate2 dosage-form groups in the Orange Book
0generic makers listed
  1. Isavuconazonium Sulfate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Cresemba. No generic is listed as marketed.

2015202020252030203501brand 2015data datePatent 10603280 listed to expire 14 September 2027Patent 10206879 listed to expire 14 September 2027Patent 10603280*PED listed to expire 14 March 2028Patent 10206879*PED listed to expire 14 March 2028Exclusivity NPP to 8 December 2026Exclusivity PED to 8 June 2027Exclusivity GAIN to 6 September 2027Exclusivity ODE-454 to 8 December 2030Exclusivity ODE-458 to 8 December 2030Exclusivity PED to 8 June 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 8 December 2026Exclusivity NPP Cresemba
  • 8 June 2027Exclusivity PED Cresemba
  • 6 September 2027Exclusivity GAIN Cresemba
  • 8 December 2030Exclusivity ODE-454 Cresemba
  • 8 December 2030Exclusivity ODE-458 Cresemba
  • 8 June 2031Exclusivity PED Cresemba
  • 14 September 2027Patent 10603280 drug product
  • 14 September 2027Patent 10206879 drug product
  • 14 March 2028Patent 10603280*PED
  • 14 March 2028Patent 10206879*PED

Powder, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Cresemba. No generic is listed as marketed.

2015202020252030203501brand 2015data dateExclusivity NPP to 8 December 2026Exclusivity PED to 8 June 2027Exclusivity GAIN to 6 September 2027Exclusivity ODE-453 to 8 December 2030Exclusivity ODE-459 to 8 December 2030Exclusivity PED to 8 June 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 8 December 2026Exclusivity NPP Cresemba
  • 8 June 2027Exclusivity PED Cresemba
  • 6 September 2027Exclusivity GAIN Cresemba
  • 8 December 2030Exclusivity ODE-453 Cresemba
  • 8 December 2030Exclusivity ODE-459 Cresemba
  • 8 June 2031Exclusivity PED Cresemba

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.